Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients

Kamile Yucel; Ali Fuat Gurbuz

doi:10.1515/hmbci-2022-0024

Article

Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients

Kamile Yucel and Ali Fuat Gurbuz

Published/Copyright: July 18, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Hormone Molecular Biology and Clinical Investigation Volume 43 Issue 4

Abstract

Objectives

In this study, it was aimed to evaluate the hypoxia-inducible factor-1α (HIF-1α) and ischemia-modified albumin (IMA) levels of patients diagnosed with COVID-19 in the intensive care unit (ICU) and healthy controls. To our knowledge, this is the first study investigate HIF-1α and IMA levels in COVID-19 patients in ICUs and comparing them with a healthy control group. For this reason, our study is original and will contribute to the literature.

Methods

A total of 70 intensive care patients diagnosed with COVID-19, and 72 healthy controls were included in the study.

Results

When we compared the patient and healthy control group; there were no statistically significant differences between the groups in terms of age and gender (p>0.05). No exitus was observed in the patient group. We found weak correlation between HIF-1α and IMA (r: 0.320). However, there were statistically significant differences in HIF-1α and IMA levels in the patient group. The receiver operating characteristic (ROC) curve demonstrated an area under curve (AUC) value of 0.651 for HIF-1α and 0.937 for IMA.

Conclusions

The HIF-1α and IMA levels were significantly higher among COVID-19 patients in ICU compared with healthy controls. HIF-1α and IMA levels can be used as reliable markers for the prognosis of COVID-19.

Keywords: COVID-19; hypoxia-inducible factor; ischemia-modified albumin; receiver operating characteristic

Corresponding author: Kamile Yucel, Department of Medical Biochemistry, KTO Karatay University, Faculty of Medicine, Konya, Turkey, Phone: 5057799883, E-mail: kamile_yucel@hotmail.com

Research funding: None declared. A brief summary of this article was presented as an oral presentation at the 7th UTSAK congress, 28/29 August 2021.
Author contributions: KY performed or analyzed serological tests. AFG obtained clinical data. KY, AFG performed statistical analysis. KY, AFG designed the study and wrote the paper. KY sent the article to the journal. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013). Ethics approval was obtained from the ethics committee of the KTO Karatay University, Health Sciences Institute, Konya, Turkey (Ethics Committee No. 2021/008, date: 08 June 2021).

References

1. Yang, ZH, Wang, B, Ma, Q, Wang, L, Lin, YX, Yan, HF, et al.. Potential mechanisms of action of Chinese patent medicines for COVID-19: a review. Front Pharmacol 2021;12:1–23. 668407. https://doi.org/10.3389/fphar.2021.668407.Search in Google Scholar PubMed PubMed Central

2. Vlachakis, D, Papakonstantinou, E, Mitsis, T, Pierouli, K, Diakou, I, Chrousos, G, et al.. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food Chem Toxicol 2020;146:1–9. 111805. https://doi.org/10.1016/j.fct.2020.111805.Search in Google Scholar PubMed PubMed Central

3. Peixoto, VR, Vieira, A, Aguiar, P, Sousa, P, Carvalho, C, Thomas, D, et al.. Determinants for hospitalisations, intensive care unit admission and death among 20.293 reported COVID-19 cases in Portugal, March to April 2020. Euro Surveill 2021;26:1–10. https://doi.org/10.2807/1560-7917.es.2021.26.33.2001059.Search in Google Scholar PubMed PubMed Central

4. Klok, FA, Kruip, MJHA, van der Meer, NJM, Arbous, MS, Gommer, DAMPJ, Kant, KM, et al.. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013.Search in Google Scholar PubMed PubMed Central

5. Etienne, EE, Nunna, BB, Talukder, N, Wang, Y, Lee, ES. COVID-19 biomarkers and advanced sensing technologies for point-of-care (POC) diagnosis. Bioengineering (Basel) 2021;8:98. https://doi.org/10.3390/bioengineering8070098.Search in Google Scholar PubMed PubMed Central

6. Qasem, A, Shaw, AM, Elkamel, E, Naser, SA. Coronavirus disease 2019 (COVID-19) diagnostic tools: a focus on detection technologies and limitations. Curr Issues Mol Biol 2021;2043:728–48. https://doi.org/10.3390/cimb43020053.Search in Google Scholar PubMed PubMed Central

7. Schönenberger, MJ, Kovacs, WJ. Hypoxia signaling pathways: modulators of oxygen-related organelles. Front Cell Dev Biol 2015;3:42.10.3389/fcell.2015.00042Search in Google Scholar PubMed PubMed Central

8. Gunton, JE. Hypoxia-inducible factors and diabetes. J Clin Invest 2020;1130:5063–73. https://doi.org/10.1172/jci137556.Search in Google Scholar PubMed PubMed Central

9. Griffiths, EA, Pritchard, SA, Welch, IM, Price, PM, West, CM. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer 2005;41:2792–805. https://doi.org/10.1016/j.ejca.2005.09.008.Search in Google Scholar PubMed

10. Marini, JJ, Gattinoni, L. Management of COVID-19 respiratory distress. JAMA 2020;323:2329–30. https://doi.org/10.1001/jama.2020.6825.Search in Google Scholar PubMed

11. Serebrovska, ZO, Chong, EY, Serebrovska, TV, Tumanovska, LV, Xi, L. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol Sin 2020;41:1539–46. https://doi.org/10.1038/s41401-020-00554-8.Search in Google Scholar PubMed PubMed Central

12. Santos, SAD, Andrade, J. HIF-1alpha and infectious diseases: a new Frontier for the development of new therapies. Rev Inst Med Trop Sao 2017;59:1–10. https://doi.org/10.1590/S1678-9946201759092.Search in Google Scholar PubMed PubMed Central

13. Jahani, M, Dokaneheifard, S, Mansouri, K. Hypoxia: a key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J Inflamm (Lond) 2020;29:33. https://doi.org/10.1186/s12950-020-00263-3.Search in Google Scholar PubMed PubMed Central

14. AbdelMassih, A, Yacoub, E, Husseiny, RJ, Kamel, A, Hozaien, R, El Shershaby, M, et al.. Hypoxia-inducible factor (HIF): the link between obesity and COVID-19. Obes Med 2021;22:1–8. 100317. https://doi.org/10.1016/j.obmed.2020.100317.Search in Google Scholar PubMed PubMed Central

15. Yildiz, H, Alp, HH, Ekin, S, Arısoy, A, Gunbatar, H, Asker, S, et al.. Analysis of endogenous oxidative damage markers and association with pulmonary involvement severity in patients with SARS-CoV-2 pneumonia. Infect Dis Now 2021;51:429–34. https://doi.org/10.1016/j.idnow.2021.06.302.Search in Google Scholar PubMed PubMed Central

16. Shevtsova, A, Gordiienko, I, Tkachenko, V, Ushakova, G. Ischemia-modified albumin: origins and clinical implications. Dis Markers 2021;19:1–18. 9945424. https://doi.org/10.1155/2021/9945424.Search in Google Scholar PubMed PubMed Central

17. Ma, SG, Wei, CL, Hong, B, Yu, WN. Ischemia modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo). 2011;66:1677–80. https://doi.org/10.1590/s1807-59322011001000003.Search in Google Scholar PubMed PubMed Central

18. Turedi, S, Gunduz, A, Mentese, A, Karahan, SC, Yilmaz, SE, Eroglu, O, et al.. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007;25:770–3. https://doi.org/10.1016/j.ajem.2006.12.013.Search in Google Scholar PubMed

19. Badawy, MA, Yasseen, BA, El-Messiery, RM, Abdelrahman, EA, Elkhodiry, AA, et al.. Neutrophil-mediated oxidative stress and albumin structural damage predict COVID-19-associated mortality. Elife 2021;10:1–22. Published 2021 Nov 25. https://doi.org/10.7554/eLife.69417.Search in Google Scholar PubMed PubMed Central

20. Alhazzani, W, Møller, MH, Arabi, YM, Loeb, M, Gong, MN, Fan, E, et al.. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48:e440–69. https://doi.org/10.1097/ccm.0000000000004363.Search in Google Scholar PubMed PubMed Central

21. Onder, G, Rezza, G, Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;12323:1775–6. https://doi.org/10.1001/jama.2020.4683.Search in Google Scholar PubMed

22. Kim, L, Garg, S, Halloran, A, Whitaker, M, Pham, H, Anderson, EJ, et al.. Interim analysis of risk factors for severe outcomes among a cohort of hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis 2021;72:e206–14. https://doi.org/10.1093/cid/ciaa1012.Search in Google Scholar PubMed PubMed Central

23. Badedi, M, Darraj, H, Alnami, AQ, Makrami, A, Mahfouz, MS, Alhazmi, K, et al.. Epidemiological and clinical characteristics of deceased COVID-19 patients. Int J Gen Med 2021;24:3809–19. https://doi.org/10.2147/ijgm.s320713.Search in Google Scholar PubMed PubMed Central

24. Ducastel, M, Chenevier-Gobeaux, C, Ballaa, Y, Meritet, JF, Brack, M, Chapuis, N, et al.. Oxidative stress and inflammatory biomarkers for the prediction of severity and ICU admission in unselected patients hospitalized with COVID-19. Int J Mol Sci 2021;1222:7462. https://doi.org/10.3390/ijms22147462.Search in Google Scholar PubMed PubMed Central

25. Cichota, LC, Moresco, RN, Duarte, MM, da Silva, JE. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008;22:1–5. https://doi.org/10.1002/jcla.20226.Search in Google Scholar PubMed PubMed Central

26. Kumar, PA, Subramanian, K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. J Clin Diagn Res 2016;10:BC09–12. https://doi.org/10.7860/JCDR/2016/17168.7399.Search in Google Scholar PubMed PubMed Central

27. Rahman, A, Tabassum, T, Araf, Y, Al Nahid, A, Ullah, MA, Hosen, MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep 2021;48:3863–9. https://doi.org/10.1007/s11033-021-06358-1.Search in Google Scholar PubMed PubMed Central

28. Afsar, B, Kanbay, M, Afsar, RE. Hypoxia inducible factor-1 protects against COVID-19: a hypothesis. Med Hypotheses 2020;143:109857. https://doi.org/10.1016/j.mehy.2020.109857.Search in Google Scholar PubMed PubMed Central

29. Goud, PT, Bai, D, Abu-Soud, HM. A multiple-hit hypothesis involving reactive oxygen species and myeloperoxidase explains clinical deterioration and fatality in COVID-19. Int J Biol Sci 2021;17:62–72. https://doi.org/10.7150/ijbs.51811.Search in Google Scholar PubMed PubMed Central

30. Öner Cengiz, H, Ayhan, M, Güner, R. Effect of deep breathing exercise with triflo on dyspnoea, anxiety and quality of life in patients receiving covid-19 treatment: a randomized controlled trial. J Clin Nurs 2021;12. Epub ahead of print. PMID: 34897869. https://doi.org/10.1111/jocn.16171.Search in Google Scholar PubMed

31. Yazıcı, MU, Ayar, G, Savas, ES, Azapağası, E, Neşelioğlu, S, Erel, Ö, et al.. Role of ischemia modified albumin serum levels as an oxidative stress marker in children with diabetic ketoacidosis. Comb Chem High Throughput Screen 2019;22:577–81. https://doi.org/10.2174/1386207322666191008214919.Search in Google Scholar PubMed

32. Sushith, S, Krishnamurthy, HN, Reshma, S, Janice, D, Madan, G, Ashok, KJ, et al.. Serum ischemia-modified albumin, fibrinogen, high sensitivity C-reactive proteins in type-2 diabetes mellitus without hypertension and diabetes mellitus with hypertension: a case-control study. Rep Biochem Mol Biol 2020;9:241–9. https://doi.org/10.29252/rbmb.9.2.241.Search in Google Scholar PubMed PubMed Central

33. Ghosh, K, Muddeshwar, MG, Ghosh, K. Ischemia modified albumin test to detect early diabetic complications. Am J Med Sci 2017;354:467–70. https://doi.org/10.1016/j.amjms.2017.06.017.Search in Google Scholar PubMed

Received: 2022-02-23

Accepted: 2022-06-07

Published Online: 2022-07-18

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/hmbci-2022-0024

Keywords for this article

COVID-19; hypoxia-inducible factor; ischemia-modified albumin; receiver operating characteristic